Divis Laboratories Ltd News

Nifty Healthcare below 100-WMA, down 8% from its peak; what charts say?

Amol Athawale of Kotak Securities believes that the short-term outlook for Nifty Healthcare remains uncertain and sentiment may turn negative in case the index falls below 13,500 levels.

Divi's Labs shares fall 3% on Q3 earnings miss; brokerages split on outlook

Divi's Laboratories reported a consolidated profit after tax (PAT) of ₹583 crore, marginally lower than ₹589 crore in the same period last year

Lupin, Biocon: Nifty Pharma gains 3% after US-India trade deal pact

According to Axis Securities, the reduction in reciprocal taxes is incrementally positive for Indian pharmaceutical companies, particularly those with significant exposure to the US market,

Indian CRDMO market to outpace APAC; HDFC Sec starts coverage on top firms

While HDFC Securities has assigned a 'Buy' rating to Divi's Labs, Sai Life Sciences, and Piramal Pharma, it has given an 'Add' rating to Anthem BioSciences and a 'Reduce' rating to Laurus Labs

JB Chem, Divis Labs among top stock recommendations by Vinay Rajani

Vinay Rajani of HDFC Securities says Divis Labs share price has broken out from the box pattern on the daily chart with the primary trend of the stock staying bullish

Pharma index hits 52-week high; Glenmark, Lupin rally 3% in subdued market

In the past two trading days, the Nifty Pharma index has rallied 3.3 per cent, as compared to 0.41 per cent decline in the Nifty 50.

Sharekhan upgrades Divi's Labs to 'Buy' on strong FY26-28 growth visibility

The brokerage said Divis Laboratories is entering a stronger growth phase, supported by a robust H2FY26 pipeline and visibility for scale-up over the next two years.

Sun Pharma sees Golden Cross; other pharma stocks with similar pattern

Technically, the term 'Golden Cross' has bullish implications with short-term support seen moving higher. Apart from Sun Pharma, Aurobindo Pharma and Divi's Labs too witnessed this formation recently.

Neuland, Lupin, Divi's lead domestic, CDMO surge amid US generics headwinds

Analysts noted that while US generics face margin headwinds, domestic formulations and CDMOs remain resilient. Biosimilars are also poised for growth through new launches and regulatory support.